多糖化物Tripterygium wilfordii通过肠道微生物群调节和代谢物重编程来缓解结性脊髓炎
Jiaqi Bi1, Yanan Yang2, Mingxi Li2
1Department of Orthopaedics, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314000, China.
Journal of advanced research
|November 24, 2025
概括
在小鼠中,Tripterygium wilfordii多糖化物 (GTW) 治疗通过调节肠道微生物群和代谢物改善了结性脊髓炎 (AS) 症状. GTW恢复了有益的细菌和代谢物,减少了炎症和疾病的严重程度.
科学领域:
- 免疫学 免疫学 免疫学
- 微生物组研究的研究.
- 药理学 药理学是指药理学的学科.
背景情况:
- 化脊柱炎 (AS) 是一种慢性自身免疫性炎症疾病,影响轴骨架.
- 多糖化 (GTW) 的Tripterygium wilfordii在临床上用于AS,但其机制尚不清楚.
研究的目的:
- 研究GTW对AS的治疗作用.
- 探索GTW对AS肠道微生物群和代谢物的影响.
主要方法:
- 一个AS小鼠模型被诱导使用蛋白质甘氨酸和弗洛伊德的完整辅助剂.
- 使用了表型分析,16S rRNA测序和代谢分析.
- 分析了肠道微生物群,代谢物和与AS相关的基因表达的变化.
主要成果:
- GTW显著降低了AS症状,包括关节炎指数和炎症.
- GTW调节了骨质细胞/骨质细胞分化,并恢复了肠道屏障的完整性.
- GTW使肠道微生物组成 (Bifidobacterium,Akkermansia) 和有益的代谢物正常化,与AS严重程度的降低相关.
结论:
- 在小鼠中,GTW改善了AS症状.
- 肠道微生物群-代谢物轴与GTW对AS的治疗作用有关.
- 需要进一步的研究来证实因果关系.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469
Inflammatory Bowel Disease IV: Pharmacological Management
452
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
452
Drugs for Treatment of Diarrhea-Predominant IBS
604
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
604
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
408
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
408
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
553
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
553
Drugs for Treatment of Ulcerative Colitis in IBD
435
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
435


